immunotherapy

Immunotherapies harness the immune system to fight disease. Biointron reviews their role in oncology and beyond, transforming treatment strategies worldwide.

ADCs for ES-SCLC. Image credit: DOI: 10.3390/genes15060701Extensive-stage small-cell lung cancer (ES-SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Antibody drugs, especially immune checkpoint inhibitors, have emerged as a promising treatme

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Why antibodies transformed immunotherapy: ADCC and CDC, checkpoint blockade, and T‑cell engagement, plus where combinations are headed against resistant tumors.